Spotlight on Oncology

Credits: 1.00 CME / CNE / CPE
The Expanding Treatment Landscape of Waldenström’s Macroglobulinemia
Steven P. Treon, MD, PhD
Rush University Medical Center

The Expanding Treatment Landscape of Waldenström’s Macroglobulinemia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 28, 2020
Expires: October 27, 2021
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.

Learning Objectives

After completing this program, participants should be able to:

  1. Summarize criteria required to accurately diagnose patients with Waldenström’s macroglobulinemia and identify those most likely to benefit from treatment
  2. Evaluate the latest clinical data on the efficacy and safety of approved and investigational therapies for patients with Waldenström’s macroglobulinemia
  3. Formulate best-practice treatment strategies for patients with Waldenström’s macroglobulinemia, taking into consideration current guidelines and expert recommendations when individualizing treatment plans

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With the recent advances in targeted therapies for WM, the use of approved and investigational agents is anticipated to expand over the coming years. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with WM and the clinical utility of agents that could significantly impact patient outcomes.

Faculty

Steven P. Treon, MD, PhD
Director, Bing Center for Waldenström's Macroglobulinemia
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA


Conflict of Interest Policy/Disclosure Statement

Dr. Treon has consulted for Janssen Pharmaceuticals, Inc., Pharmacyclics, Inc., and BeiGene, Inc.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 1.0 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 1.0 continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Janssen Biotech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 28, 2020
Expires: October 27, 2021
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.

Learning Objectives

After completing this program, participants should be able to:

  1. Summarize criteria required to accurately diagnose patients with Waldenström’s macroglobulinemia and identify those most likely to benefit from treatment
  2. Evaluate the latest clinical data on the efficacy and safety of approved and investigational therapies for patients with Waldenström’s macroglobulinemia
  3. Formulate best-practice treatment strategies for patients with Waldenström’s macroglobulinemia, taking into consideration current guidelines and expert recommendations when individualizing treatment plans

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With the recent advances in targeted therapies for WM, the use of approved and investigational agents is anticipated to expand over the coming years. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with WM and the clinical utility of agents that could significantly impact patient outcomes.

Faculty

Steven P. Treon, MD, PhD
Director, Bing Center for Waldenström's Macroglobulinemia
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA


Conflict of Interest Policy/Disclosure Statement

Dr. Treon has consulted for Janssen Pharmaceuticals, Inc., Pharmacyclics, Inc., and BeiGene, Inc.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 1.0 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 1.0 continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Janssen Biotech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Oncology Presentations

0.50 CME
Postgraduate Institute for Medicine
On Topic Virtual Roundtable™: Deciphering the Decisions in Newly Diagnosed Advanced Ovarian Cancer

On Topic Virtual Roundtable™: Deciphering the Decisions in Newly Diagnosed Advanced Ovarian Cancer

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: October 7, 2021
Expires: October 7, 2022
30 minutes to complete

Jointly Provided By

The Postgraduate Institute for Medicine and Bio Ascend

Target Audience

The target audience for this activity is community and academic medical oncologists, gynecologic oncologists, surgical oncologists, obstetricians and gynecologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with ovarian cancer.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Select genetic testing for patients with newly diagnosed advanced ovarian cancer
  • Utilize clinical features and genetic information to plan treatment for patients with newly diagnosed advanced ovarian cancer
  • Compare and contrast current and emerging treatment strategies for patients with newly diagnosed ovarian cancer
  • Manage adverse events associated with maintenance therapy for patients with newly diagnosed advanced ovarian cancer

Activity Description

On Topic Virtual Roundtable™: Deciphering the Decisions in Newly Diagnosed Advanced Ovarian Cancer aims to focus on critical care decisions for patients with newly diagnosed advanced ovarian cancer. This activity will also provide a unique take by including the patient voice as part of the discussion. You’ll hear directly from a patient living with ovarian cancer who will share her experience along with important information she feels physicians should know when caring for these patients.

Statement of Educational Need

Ovarian neoplasms, consisting mostly of epithelial ovarian cancer (~90%), is the leading cause of death from gynecologic cancer in the United States. Improved outcomes from multiple phase 3 studies have shifted the treatment paradigm for patients with newly diagnosed advanced ovarian cancer. This progress brings new challenges, which force HCPs to make critical decisions that require extensive knowledge and careful thought. This program will help clinicians make those critical decisions leading to improved care for patients with this challenging disease.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator

Robert Coleman, MD, FACS, FACOG
Chief Scientific Officer
Texas Oncology - US Oncology Research
Houston, Texas

Consultant/Advisory Board: Deciphera, Agenus, Gradalis, Alkermes, Epsilogen, Karyopharm, Merck, GSK, Seagen, Slovis, Novocure, DNAMx, AstraZeneca, Genelux, Genentech/Roche, Abbvie, OncXerna
Research Funding: Merck, Abbvie, AstraZeneca, Seagen, Genentech/Roche

Faculty

Angeles Alvarez Secord, MD
Professor of Obstetrics and Gynecology
Duke Cancer Institute
Durham, North Carolina

Consulting Fees/Advisory Board: Myriad, AbbVie, Aravive, AstraZeneca, Eisai, Tesaro/GSK, Regeneron
Research Funding: AbbVie, AstraZeneca, Boehringer Ingelheim, Clovis, Eisai, Immutep Ltd, Merck, Oncoquest, PharmaMar, Roche/Genentech, Seagen Inc., Tesaro/GSK, VBL Therapeutics, National Cancer Trial Network


Paula Anastasia, RN, MN, AOCN
GYN-Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, California

Consulting Fees: Merck Advisory Board
Speakers’ Bureau (non-branded): Genentech


Patient Advocate and Ovarian Cancer Survivor
Kathy Jennings


No relevant financial relationships to disclose

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca and Merck.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: October 7, 2021
Expires: October 7, 2022
30 minutes to complete

Jointly Provided By

The Postgraduate Institute for Medicine and Bio Ascend

Target Audience

The target audience for this activity is community and academic medical oncologists, gynecologic oncologists, surgical oncologists, obstetricians and gynecologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with ovarian cancer.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Select genetic testing for patients with newly diagnosed advanced ovarian cancer
  • Utilize clinical features and genetic information to plan treatment for patients with newly diagnosed advanced ovarian cancer
  • Compare and contrast current and emerging treatment strategies for patients with newly diagnosed ovarian cancer
  • Manage adverse events associated with maintenance therapy for patients with newly diagnosed advanced ovarian cancer

Activity Description

On Topic Virtual Roundtable™: Deciphering the Decisions in Newly Diagnosed Advanced Ovarian Cancer aims to focus on critical care decisions for patients with newly diagnosed advanced ovarian cancer. This activity will also provide a unique take by including the patient voice as part of the discussion. You’ll hear directly from a patient living with ovarian cancer who will share her experience along with important information she feels physicians should know when caring for these patients.

Statement of Educational Need

Ovarian neoplasms, consisting mostly of epithelial ovarian cancer (~90%), is the leading cause of death from gynecologic cancer in the United States. Improved outcomes from multiple phase 3 studies have shifted the treatment paradigm for patients with newly diagnosed advanced ovarian cancer. This progress brings new challenges, which force HCPs to make critical decisions that require extensive knowledge and careful thought. This program will help clinicians make those critical decisions leading to improved care for patients with this challenging disease.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator

Robert Coleman, MD, FACS, FACOG
Chief Scientific Officer
Texas Oncology - US Oncology Research
Houston, Texas

Consultant/Advisory Board: Deciphera, Agenus, Gradalis, Alkermes, Epsilogen, Karyopharm, Merck, GSK, Seagen, Slovis, Novocure, DNAMx, AstraZeneca, Genelux, Genentech/Roche, Abbvie, OncXerna
Research Funding: Merck, Abbvie, AstraZeneca, Seagen, Genentech/Roche

Faculty

Angeles Alvarez Secord, MD
Professor of Obstetrics and Gynecology
Duke Cancer Institute
Durham, North Carolina

Consulting Fees/Advisory Board: Myriad, AbbVie, Aravive, AstraZeneca, Eisai, Tesaro/GSK, Regeneron
Research Funding: AbbVie, AstraZeneca, Boehringer Ingelheim, Clovis, Eisai, Immutep Ltd, Merck, Oncoquest, PharmaMar, Roche/Genentech, Seagen Inc., Tesaro/GSK, VBL Therapeutics, National Cancer Trial Network


Paula Anastasia, RN, MN, AOCN
GYN-Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, California

Consulting Fees: Merck Advisory Board
Speakers’ Bureau (non-branded): Genentech


Patient Advocate and Ovarian Cancer Survivor
Kathy Jennings


No relevant financial relationships to disclose

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca and Merck.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com

0.25 CME
University of Nebraska Medical Center
Expert Insights: Expert Tumor Board to Address Challenging Cases of Relapsed/Refractory Aggressive and Indolent Lymphomas

Expert Insights: Expert Tumor Board to Address Challenging Cases of Relapsed/Refractory Aggressive and Indolent Lymphomas

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: September 24, 2021
Expires: September 24, 2022
15 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Assess current and emerging approaches to the treatment of patients with aggressive B-cell lymphoma, and optimal patient management strategies
  • Evaluate clinical trial data of both approved and novel agents and regimens being investigated in patients with indolent lymphoma
  • Discuss approaches to the care of patients with rare lymphoma subtypes, including Burkitt lymphoma and peripheral T-cell lymphoma

Activity Description

Major advances in the diagnosis and treatment of aggressive lymphoma have occurred in the past few years. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, and early interventions as a potential cure. As we go forward with these strategies, clinicians treating patients with lymphoma need expert guidance to evaluate best practices and emerging clinical data and plan strategies to apply them safely and effectively to their patients. This educational activity provides a discussion between two lymphoma experts as they explore challenging, real-world case scenarios in DLBCL, MCL, and rare aggressive lymphoma subtypes.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with aggressive lymphoma subtypes (including diffuse large B-cell lymphoma [DLBCL], mantle cell lymphoma [MCL], and others), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs.

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty
Ranjana Advani, MD
CONSULTANT: ADC Therapeutics; BeiGene; Daiichi Sankyo; Incyte Corp.; Karyopharm; Kura; Portola Pharmaceuticals; Sanofi

RESEARCH FUNDING: Bristol Myers Squibb; Celgene; Kura; Merck; Roche/Genentech; Seattle Genetics; Takeda/Millennium

ADVISORY BOARD: Roche/Genentech

HONORARIUM: Roche/Genentech

Matthew Lunning, DO, FACP
CONSULTANT: Acrotech Biopharma; AstraZeneca/Acerta; Beigene; Bristol Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen/Pharmacyclics; Karyopharm; Kite; Legend Pharmaceuticals; MorphoSys; Myeloid Therapeutics; Spectrum; TG Therapeutics; Verastem

RESEARCH GRANT SUPPORT: Bristol Myers Squibb; Curis

ADVISORY BOARD: Celgene

Planning Committee
The following planning committee members have nothing to disclose:

UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Chloe Dunnam; Kraig Steubing; Dru Dace, PhD

Faculty

Moderator
Matthew Lunning, DO, FACP
Associate Professor
Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska


Ranjana Advani, MD
Saul A. Rosenberg Professor of Lymphoma
Physician Leader, Lymphoma Critical Care Program
Stanford Cancer Institute
Palo Alto, California

Continuing Education

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from Daiichi-Sankyo, Inc., Genentech, a member of the Roche Group, Incyte Corporation, MorphoSys, and TG Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: September 24, 2021
Expires: September 24, 2022
15 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Assess current and emerging approaches to the treatment of patients with aggressive B-cell lymphoma, and optimal patient management strategies
  • Evaluate clinical trial data of both approved and novel agents and regimens being investigated in patients with indolent lymphoma
  • Discuss approaches to the care of patients with rare lymphoma subtypes, including Burkitt lymphoma and peripheral T-cell lymphoma

Activity Description

Major advances in the diagnosis and treatment of aggressive lymphoma have occurred in the past few years. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, and early interventions as a potential cure. As we go forward with these strategies, clinicians treating patients with lymphoma need expert guidance to evaluate best practices and emerging clinical data and plan strategies to apply them safely and effectively to their patients. This educational activity provides a discussion between two lymphoma experts as they explore challenging, real-world case scenarios in DLBCL, MCL, and rare aggressive lymphoma subtypes.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with aggressive lymphoma subtypes (including diffuse large B-cell lymphoma [DLBCL], mantle cell lymphoma [MCL], and others), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs.

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty
Ranjana Advani, MD
CONSULTANT: ADC Therapeutics; BeiGene; Daiichi Sankyo; Incyte Corp.; Karyopharm; Kura; Portola Pharmaceuticals; Sanofi

RESEARCH FUNDING: Bristol Myers Squibb; Celgene; Kura; Merck; Roche/Genentech; Seattle Genetics; Takeda/Millennium

ADVISORY BOARD: Roche/Genentech

HONORARIUM: Roche/Genentech

Matthew Lunning, DO, FACP
CONSULTANT: Acrotech Biopharma; AstraZeneca/Acerta; Beigene; Bristol Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen/Pharmacyclics; Karyopharm; Kite; Legend Pharmaceuticals; MorphoSys; Myeloid Therapeutics; Spectrum; TG Therapeutics; Verastem

RESEARCH GRANT SUPPORT: Bristol Myers Squibb; Curis

ADVISORY BOARD: Celgene

Planning Committee
The following planning committee members have nothing to disclose:

UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Chloe Dunnam; Kraig Steubing; Dru Dace, PhD

Faculty

Moderator
Matthew Lunning, DO, FACP
Associate Professor
Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska


Ranjana Advani, MD
Saul A. Rosenberg Professor of Lymphoma
Physician Leader, Lymphoma Critical Care Program
Stanford Cancer Institute
Palo Alto, California

Continuing Education

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from Daiichi-Sankyo, Inc., Genentech, a member of the Roche Group, Incyte Corporation, MorphoSys, and TG Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

1.00 CME / CNE / CPE
Rush University Medical Center
Best Clinical Practices for Optimizing the Use of BTK Inhibitors for the Treatment of CLL

Best Clinical Practices for Optimizing the Use of BTK Inhibitors for the Treatment of CLL

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: September 24, 2021
Expires:September 23, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.

Learning Objectives

After completing this program, participants should be able to:

  • Differentiate the characteristics and clinical outcomes associated with FDA-approved BTK inhibitors
  • Analyze the safety and efficacy of BTK inhibitors for the treatment of CLL
  • Summarize emerging approaches for using BTK inhibitors to treat CLL, including combination therapy and sequencing considerations
  • Formulate individualized treatment plans for patients in the VHA/MHS/DoD system with CLL based on intrinsic characteristics of the patient, the disease, and the treatment

Activity Description

With the recent advances in targeted BTK inhibitor therapies for CLL, the use of approved and investigational agents is anticipated to expand over the coming years. The introduction of first- and second-generation BTK inhibitors into the clinic have provided additional effective treatment options but have also created uncertainty over differences in mechanism of action, pharmacologic properties, efficacy, and safety among the available agents. This activity will help clinicians to be better prepared with a comprehensive understanding of the appropriate clinical utility of BTK inhibitors that could significantly impact patient outcomes. The expert guidance and interpretation of the clinical significance of emerging clinical data provided in this activity, will help to improve the ease of assessment and incorporation of BTK inhibitors into clinical practice.

Statement of Educational Need

To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate clinical utility of BTK inhibitors that could significantly impact patient outcomes.

Faculty

Matthew Davids, MD, MMSc
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Conflict of Interest Policy/Disclosure Statement

Dr. Davids has research grants from:
AbbVie, Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, Verastem

Dr. Davids has consulted for:
AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Eli Lilly, Genentech, Janssen, MEI Pharma, Merck, Novartis, Pharmacyclics, Research to Practice, TG Therapeutics, Verastem, Zentalis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this online activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this online activity for a maximum of one (1.0) continuing nursing education credit(s).

Rush University Medical Center designates this online activity for a maximum of one (1.0) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Astra Zeneca, Beigene, Janssen Biotech, Inc., and Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: September 24, 2021
Expires:September 23, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.

Learning Objectives

After completing this program, participants should be able to:

  • Differentiate the characteristics and clinical outcomes associated with FDA-approved BTK inhibitors
  • Analyze the safety and efficacy of BTK inhibitors for the treatment of CLL
  • Summarize emerging approaches for using BTK inhibitors to treat CLL, including combination therapy and sequencing considerations
  • Formulate individualized treatment plans for patients in the VHA/MHS/DoD system with CLL based on intrinsic characteristics of the patient, the disease, and the treatment

Activity Description

With the recent advances in targeted BTK inhibitor therapies for CLL, the use of approved and investigational agents is anticipated to expand over the coming years. The introduction of first- and second-generation BTK inhibitors into the clinic have provided additional effective treatment options but have also created uncertainty over differences in mechanism of action, pharmacologic properties, efficacy, and safety among the available agents. This activity will help clinicians to be better prepared with a comprehensive understanding of the appropriate clinical utility of BTK inhibitors that could significantly impact patient outcomes. The expert guidance and interpretation of the clinical significance of emerging clinical data provided in this activity, will help to improve the ease of assessment and incorporation of BTK inhibitors into clinical practice.

Statement of Educational Need

To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate clinical utility of BTK inhibitors that could significantly impact patient outcomes.

Faculty

Matthew Davids, MD, MMSc
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Conflict of Interest Policy/Disclosure Statement

Dr. Davids has research grants from:
AbbVie, Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, Verastem

Dr. Davids has consulted for:
AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Eli Lilly, Genentech, Janssen, MEI Pharma, Merck, Novartis, Pharmacyclics, Research to Practice, TG Therapeutics, Verastem, Zentalis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this online activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this online activity for a maximum of one (1.0) continuing nursing education credit(s).

Rush University Medical Center designates this online activity for a maximum of one (1.0) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Astra Zeneca, Beigene, Janssen Biotech, Inc., and Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

0.25 CME
Postgraduate Institute for Medicine
Expert Insights: Practical Aspects of Incorporating CAR T-Cell Therapy into Your Practice

Expert Insights: Practical Aspects of Incorporating CAR T-Cell Therapy into Your Practice

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: September 9, 2021
Expires: September 9, 2022
15 minutes to complete

Accredited By

The Postgraduate Institute for Medicine

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma and myeloma.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Incorporate CAR T-cell therapy into clinical practice, and identify appropriate patients
  • Develop strategies to mitigate treatment-related adverse events that may occur during treatment with CAR T-cell therapy
  • Discuss the emerging results of clinical trials that are investigating CAR T-cell therapies in lymphoma and myeloma
  • Optimize the referral process and multidisciplinary care for patients who qualify for CAR T-cell therapy

Faculty Disclosures

All faculty and planning committee members have no conflicts to disclose with the exception of the following:

Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Consultant Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis


Loretta Nastoupil, MD
Associate Professor, Department of Lymphoma and Myeloma
Director, Lymphoma Outcomes Database
Section Chief, New Drug Development
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Consultant Fees: Celgene, Genentech, Gilead/Kite, Janssen, Novartis, Pfizer, Takeda, TG Therapeutics
Contracted Research: Celgene, Epizyme, Genentech, Gilead/Kite, Janssen, Novartis, Pfizer, Merck, Takeda

Planning Committee
The PIM planners and managers have nothing to disclose. The Bio Ascend LLC planners and managers have nothing to disclose.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from Janssen Scientific Affairs, LLC and Legend Biotech.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: September 9, 2021
Expires: September 9, 2022
15 minutes to complete

Accredited By

The Postgraduate Institute for Medicine

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma and myeloma.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Incorporate CAR T-cell therapy into clinical practice, and identify appropriate patients
  • Develop strategies to mitigate treatment-related adverse events that may occur during treatment with CAR T-cell therapy
  • Discuss the emerging results of clinical trials that are investigating CAR T-cell therapies in lymphoma and myeloma
  • Optimize the referral process and multidisciplinary care for patients who qualify for CAR T-cell therapy

Faculty Disclosures

All faculty and planning committee members have no conflicts to disclose with the exception of the following:

Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Consultant Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis


Loretta Nastoupil, MD
Associate Professor, Department of Lymphoma and Myeloma
Director, Lymphoma Outcomes Database
Section Chief, New Drug Development
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Consultant Fees: Celgene, Genentech, Gilead/Kite, Janssen, Novartis, Pfizer, Takeda, TG Therapeutics
Contracted Research: Celgene, Epizyme, Genentech, Gilead/Kite, Janssen, Novartis, Pfizer, Merck, Takeda

Planning Committee
The PIM planners and managers have nothing to disclose. The Bio Ascend LLC planners and managers have nothing to disclose.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from Janssen Scientific Affairs, LLC and Legend Biotech.

Contact Information for Questions About the Activity

info@bioascend.com

0.75 CME
University of Nebraska Medical Center
Podium to Practice: Navigating the New Landscape in Relapsed/Refractory Multiple Myeloma – Clinical Impact of Recently Presented Data

Podium to Practice: Navigating the New Landscape in Relapsed/Refractory Multiple Myeloma – Clinical Impact of Recently Presented Data

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: August 30, 2021
Expires: August 30, 2022
45 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Incorporate minimal residual disease assessment when evaluating prognosis and potential relapse
  • Evaluate treatment approaches for patients with relapsed and/or refractory MM, specifically the decision to include a monoclonal bispecific antibody, or antibody-drug conjugate, CAR T cell therapy, and combination with other agents for triplet therapy
  • Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with RR MM
  • Discuss the results of clinical trials that are investigating emerging novel agents in patients with RR MM

Activity Description

The treatment of MM has changed dramatically in the past decade. While MM remains an incurable disease, advances in therapy have resulted in a marked improvement in overall survival (OS). New therapies have been approved including novel proteasome inhibitors and antibodies. With so many new available agents, many clinical questions arise, including ideal sequencing of agents, role of MRD, management of adverse events, and incorporating emerging data of investigational agents. This activity will provide expert interpretation of recently presented data regarding currently available and emerging therapies for the treatment of patients with relapsed or refractory multiple myeloma.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with relapsed/refractory multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials exploring novel agents, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with relapsed/refractory MM.

Moderator

Cristina Gasparetto, MD
Professor of Medicine, Hematologic Malignancies and Cellular Therapy
Duke University School of Medicine
Durham, North Carolina

Faculty

Maria-Victoria Mateos, MD, PhD
Associate Professor of Hematology
Director, Myeloma Unit
University Hospital of Salamanca
Salamanca, Spain

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Cristina Gasparetto, MD (Moderator)
Consulting Fees: AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Inc., Sanofi
Contracted Research: GlaxoSmithKline

Maria-Victoria Mateos, MD, PhD
Honorarium (Lectures): Adaptive Biotechnologies, Amgen, Bristol Myers Squibb/Celgene Corporation, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Inc., Sanofi, Takeda
Honorarium (Advisory Boards): Adaptive Biotechnologies, Amgen, Bluebird Bio, Bristol Myers Squibb/Celgene Corporation, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Inc., Pfizer Inc., Regeneron, Roche, Sanofi, SeaGen, Takeda

Planning Committee
The following planning committee members have nothing to disclose:

UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Dru Dace, PhD; Chloe Dunnam; Kraig Steubing

Accreditation Statement

Continuing Education
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AbbVie, Inc., Karyopharm Therapeutics, Legend Biotech, Oncopeptides, Inc., and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: August 30, 2021
Expires: August 30, 2022
45 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Incorporate minimal residual disease assessment when evaluating prognosis and potential relapse
  • Evaluate treatment approaches for patients with relapsed and/or refractory MM, specifically the decision to include a monoclonal bispecific antibody, or antibody-drug conjugate, CAR T cell therapy, and combination with other agents for triplet therapy
  • Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with RR MM
  • Discuss the results of clinical trials that are investigating emerging novel agents in patients with RR MM

Activity Description

The treatment of MM has changed dramatically in the past decade. While MM remains an incurable disease, advances in therapy have resulted in a marked improvement in overall survival (OS). New therapies have been approved including novel proteasome inhibitors and antibodies. With so many new available agents, many clinical questions arise, including ideal sequencing of agents, role of MRD, management of adverse events, and incorporating emerging data of investigational agents. This activity will provide expert interpretation of recently presented data regarding currently available and emerging therapies for the treatment of patients with relapsed or refractory multiple myeloma.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with relapsed/refractory multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials exploring novel agents, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with relapsed/refractory MM.

Moderator

Cristina Gasparetto, MD
Professor of Medicine, Hematologic Malignancies and Cellular Therapy
Duke University School of Medicine
Durham, North Carolina

Faculty

Maria-Victoria Mateos, MD, PhD
Associate Professor of Hematology
Director, Myeloma Unit
University Hospital of Salamanca
Salamanca, Spain

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Cristina Gasparetto, MD (Moderator)
Consulting Fees: AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Inc., Sanofi
Contracted Research: GlaxoSmithKline

Maria-Victoria Mateos, MD, PhD
Honorarium (Lectures): Adaptive Biotechnologies, Amgen, Bristol Myers Squibb/Celgene Corporation, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Inc., Sanofi, Takeda
Honorarium (Advisory Boards): Adaptive Biotechnologies, Amgen, Bluebird Bio, Bristol Myers Squibb/Celgene Corporation, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Inc., Pfizer Inc., Regeneron, Roche, Sanofi, SeaGen, Takeda

Planning Committee
The following planning committee members have nothing to disclose:

UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Dru Dace, PhD; Chloe Dunnam; Kraig Steubing

Accreditation Statement

Continuing Education
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AbbVie, Inc., Karyopharm Therapeutics, Legend Biotech, Oncopeptides, Inc., and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

0.50 CME
University of Nebraska Medical Center
On Topic Virtual Roundtable: Multidisciplinary Perspectives on the Changing Care of Relapsed/Refractory Multiple Myeloma

On Topic Virtual Roundtable: Multidisciplinary Perspectives on the Changing Care of Relapsed/Refractory Multiple Myeloma

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: August 24, 2021
Expires: August 24, 2022
30 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Discuss factors that impact the selection of therapy for patients at first relapse, including certain patient- and disease-related factors, as well as previous agents received
  • Assess treatment strategies for patients with MM that are in their 2nd relapse and beyond, including the incorporation of recently approved agents and the potential for clinical trial enrollment exploring novel regimens
  • Develop strategies to optimize patient related outcomes, including mitigating adverse events, improving quality of life, and recognizing the role of the patient voice in selecting therapeutic approaches

Activity Description

Major advances in the diagnosis and treatment of MM have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. As we go forward with these strategies, clinicians treating patients with MM need expert guidance to evaluate best practices and emerging clinical data and plan strategies to apply them safely and effectively to their patients. This educational activity aims to provide community-based clinicians with clinical recommendations to address treatment options for patients with R/R MM via myeloma experts.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with relapsed/refractory multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials exploring novel agents, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with relapsed/refractory MM.

Agenda

Setting the Stage for Success

The Changing Therapeutic Landscape for Relapsed/Refractory Multiple Myeloma

Practical Approaches to Patient-Centered Care

Key Takeaways

Moderator

Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute
Adjunct Professor, College of Health Solutions, Arizona State University
Phoenix, Arizona

Faculty

Caitlin Costello, MD
Associate Clinical Professor of Medicine
UC San Diego Health
UCSD/Sharp Healthcare Transplant Program
Blood & Marrow Transplant Services
Moores Cancer Center
La Jolla, California


Sandra Kurtin, PhD, ANP-C, AOCN
Assistant Professor of Clinical Medicine
Assistant Professor of Nursing
The University of Arizona Cancer Center
Tucson, Arizona

Patient Advocate

Tom Tucker
Co-Leader, Multiple Myeloma San Diego Support Group
15-year Multiple Myeloma Survivor

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education.  Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.  All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty and Patient Advocate
Joseph Mikhael, MD, MEd, FRCPC, FACP (Moderator)
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Sanofi

Caitlin Costello, MD
Consultant/Research Funding: Bristol Myers Squibb Company, Janssen, Takeda

Sandra Kurtin, PhD, ANP-C, AOCN
Consultant: Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline, Sanofi, Incyte Corporation

Tom Tucker
No relevant financial relationships to disclose

Planning Committee
The following planning committee members have nothing to disclose except for the following:

Sara Fagerlie, PhD, CHCP
Consultant: Adaptive Biotechnologies

UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Chloe Dunnam; Kraig Steubing

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend.  University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and Conflict of Interest disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AbbVie, Karyopharm, Sanofi, and Oncopeptides.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: August 24, 2021
Expires: August 24, 2022
30 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Discuss factors that impact the selection of therapy for patients at first relapse, including certain patient- and disease-related factors, as well as previous agents received
  • Assess treatment strategies for patients with MM that are in their 2nd relapse and beyond, including the incorporation of recently approved agents and the potential for clinical trial enrollment exploring novel regimens
  • Develop strategies to optimize patient related outcomes, including mitigating adverse events, improving quality of life, and recognizing the role of the patient voice in selecting therapeutic approaches

Activity Description

Major advances in the diagnosis and treatment of MM have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. As we go forward with these strategies, clinicians treating patients with MM need expert guidance to evaluate best practices and emerging clinical data and plan strategies to apply them safely and effectively to their patients. This educational activity aims to provide community-based clinicians with clinical recommendations to address treatment options for patients with R/R MM via myeloma experts.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with relapsed/refractory multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials exploring novel agents, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with relapsed/refractory MM.

Agenda

Setting the Stage for Success

The Changing Therapeutic Landscape for Relapsed/Refractory Multiple Myeloma

Practical Approaches to Patient-Centered Care

Key Takeaways

Moderator

Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute
Adjunct Professor, College of Health Solutions, Arizona State University
Phoenix, Arizona

Faculty

Caitlin Costello, MD
Associate Clinical Professor of Medicine
UC San Diego Health
UCSD/Sharp Healthcare Transplant Program
Blood & Marrow Transplant Services
Moores Cancer Center
La Jolla, California


Sandra Kurtin, PhD, ANP-C, AOCN
Assistant Professor of Clinical Medicine
Assistant Professor of Nursing
The University of Arizona Cancer Center
Tucson, Arizona

Patient Advocate

Tom Tucker
Co-Leader, Multiple Myeloma San Diego Support Group
15-year Multiple Myeloma Survivor

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education.  Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.  All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty and Patient Advocate
Joseph Mikhael, MD, MEd, FRCPC, FACP (Moderator)
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Sanofi

Caitlin Costello, MD
Consultant/Research Funding: Bristol Myers Squibb Company, Janssen, Takeda

Sandra Kurtin, PhD, ANP-C, AOCN
Consultant: Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline, Sanofi, Incyte Corporation

Tom Tucker
No relevant financial relationships to disclose

Planning Committee
The following planning committee members have nothing to disclose except for the following:

Sara Fagerlie, PhD, CHCP
Consultant: Adaptive Biotechnologies

UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Chloe Dunnam; Kraig Steubing

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend.  University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and Conflict of Interest disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AbbVie, Karyopharm, Sanofi, and Oncopeptides.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

0.50 CME
Postgraduate Institute for Medicine
Expert Insights: New Targets, New Agents, New Combinations: Navigating the New Landscape in Relapsed/Refractory Multiple Myeloma

Expert Insights: New Targets, New Agents, New Combinations: Navigating the New Landscape in Relapsed/Refractory Multiple Myeloma

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: August 5, 2021
Expires: August 5, 2022
30 minutes to complete

Accredited By

The Postgraduate Institute for Medicine

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Evaluate treatment approaches for patients with relapsed and/or refractory MM specifically the decision to include a monoclonal antibody or antibody-drug conjugate, and combination with other agents for triplet therapy
  • Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with MM
  • Discuss the results of clinical trials that are investigating emerging novel agents in patients with MM

Activity Description

Major advances in the diagnosis and treatment of multiple myeloma (MM) have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. This educational activity will highlight the most clinically relevant data and its potential impact on current and future strategies for the treatment of relapsed/refractory multiple myeloma.

Statement of Educational Need

Multiple myeloma (MM) is a clonal plasma cell malignant neoplasm that accounts for 1% of all cancers and ~10% of all hematologic malignancies. The treatment of MM has changed dramatically in the past decade. While MM remains an incurable disease, advances in therapy have resulted in a marked improvement in overall survival (OS). New therapies have been approved including novel proteasome inhibitors and antibodies. With so many new available agents, particularly in the relapsed/refractory MM setting, questions of ideal sequencing of agents, management of adverse events, and incorporating emerging data of investigational agents will require expert guidance and interpretation of newly released data.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator

Noopur Raje, MD
Professor of Medicine, Harvard Medical School
Director, Multiple Myeloma Program, Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Consultant/Advisory Board: Celgene, Takeda, Amgen Inc., Novartis, Janssen, Bristol Myers Squibb Company, Merck, Pfizer, Bluebird Bio, Caribou Biosciences, Immuneel Therapeutics
Research Funding: Bluebird Bio

Faculty

Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute
Adjunct Professor, College of Health Solutions, Arizona State University
Phoenix, Arizona

Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Sanofi

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from Oncopeptides and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: August 5, 2021
Expires: August 5, 2022
30 minutes to complete

Accredited By

The Postgraduate Institute for Medicine

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Evaluate treatment approaches for patients with relapsed and/or refractory MM specifically the decision to include a monoclonal antibody or antibody-drug conjugate, and combination with other agents for triplet therapy
  • Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with MM
  • Discuss the results of clinical trials that are investigating emerging novel agents in patients with MM

Activity Description

Major advances in the diagnosis and treatment of multiple myeloma (MM) have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. This educational activity will highlight the most clinically relevant data and its potential impact on current and future strategies for the treatment of relapsed/refractory multiple myeloma.

Statement of Educational Need

Multiple myeloma (MM) is a clonal plasma cell malignant neoplasm that accounts for 1% of all cancers and ~10% of all hematologic malignancies. The treatment of MM has changed dramatically in the past decade. While MM remains an incurable disease, advances in therapy have resulted in a marked improvement in overall survival (OS). New therapies have been approved including novel proteasome inhibitors and antibodies. With so many new available agents, particularly in the relapsed/refractory MM setting, questions of ideal sequencing of agents, management of adverse events, and incorporating emerging data of investigational agents will require expert guidance and interpretation of newly released data.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator

Noopur Raje, MD
Professor of Medicine, Harvard Medical School
Director, Multiple Myeloma Program, Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Consultant/Advisory Board: Celgene, Takeda, Amgen Inc., Novartis, Janssen, Bristol Myers Squibb Company, Merck, Pfizer, Bluebird Bio, Caribou Biosciences, Immuneel Therapeutics
Research Funding: Bluebird Bio

Faculty

Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute
Adjunct Professor, College of Health Solutions, Arizona State University
Phoenix, Arizona

Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Sanofi

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from Oncopeptides and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com

1.00 CME / CNE / CPE
Rush University Medical Center
Optimizing Outcomes in Non-Small Cell Lung Cancer: Advances in the Management of EGFR-Mutated Disease

Optimizing Outcomes in Non-Small Cell Lung Cancer: Advances in the Management of EGFR-Mutated Disease

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: August 2, 2021
Expires: August 1, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with non-small cell lung cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Describe guideline-recommended biomarker testing in NSCLC and how the results can inform clinical decision-making.
  2. Evaluate the latest clinical evidence regarding the safety and efficacy of recently approved therapies for EGFR-mutated NSCLC.
  3. Incorporate an understanding of the mechanisms of action and clinical data regarding approved EGFR-targeted therapies into the management of patients who progress after first-line EGFR TKI therapy for NSCLC.
  4. Outline the mechanisms of action for emerging agents directed against EGFR mutations in NSCLC.
  5. Assess available clinical data for investigational agents targeting EGFR and their potential roles in the context of existing NSCLC treatment paradigms.

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of non-small cell lung cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

This educational programming is designed to provide the healthcare team with the latest developments and critical insights into the management of EGFR-mutated non-small cell lung cancer (NSCLC). This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Faculty

Stephen V. Liu, MD
Associate Professor of Medicine,
Director of Thoracic Oncology and Director of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center
Washington, DC

Conflict of Interest Policy/Disclosure Statement

Dr. Liu has consulted for:
Amgen, AstraZeneca, Beigene, Blueprint, Bristol-Myers Squibb, Daiichi Sankyo, Elevation Oncology, G1 Therapeutics, Genentech/Roche, Guardant Health, Inivata, Janssen, Jazz Pharmaceuticals, Lilly, Merck/MSD, Pfizer, PharmaMar, Regeneron, Takeda, Turning Point Therapeutics

Dr. Liu has research grants from:
Alkermes, Bayer, Blueprint, Bristol-Myers Squibb, Elevation Oncology, Genentech, Lilly, Merck, Merus, Pfizer, Rain Therapeutics, RAPT, Turning Point Therapeutics (all to institution)

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Astra Zeneca and Janssen Biotech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: August 2, 2021
Expires: August 1, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with non-small cell lung cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Describe guideline-recommended biomarker testing in NSCLC and how the results can inform clinical decision-making.
  2. Evaluate the latest clinical evidence regarding the safety and efficacy of recently approved therapies for EGFR-mutated NSCLC.
  3. Incorporate an understanding of the mechanisms of action and clinical data regarding approved EGFR-targeted therapies into the management of patients who progress after first-line EGFR TKI therapy for NSCLC.
  4. Outline the mechanisms of action for emerging agents directed against EGFR mutations in NSCLC.
  5. Assess available clinical data for investigational agents targeting EGFR and their potential roles in the context of existing NSCLC treatment paradigms.

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of non-small cell lung cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

This educational programming is designed to provide the healthcare team with the latest developments and critical insights into the management of EGFR-mutated non-small cell lung cancer (NSCLC). This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Faculty

Stephen V. Liu, MD
Associate Professor of Medicine,
Director of Thoracic Oncology and Director of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center
Washington, DC

Conflict of Interest Policy/Disclosure Statement

Dr. Liu has consulted for:
Amgen, AstraZeneca, Beigene, Blueprint, Bristol-Myers Squibb, Daiichi Sankyo, Elevation Oncology, G1 Therapeutics, Genentech/Roche, Guardant Health, Inivata, Janssen, Jazz Pharmaceuticals, Lilly, Merck/MSD, Pfizer, PharmaMar, Regeneron, Takeda, Turning Point Therapeutics

Dr. Liu has research grants from:
Alkermes, Bayer, Blueprint, Bristol-Myers Squibb, Elevation Oncology, Genentech, Lilly, Merck, Merus, Pfizer, Rain Therapeutics, RAPT, Turning Point Therapeutics (all to institution)

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Astra Zeneca and Janssen Biotech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

1.00 CME / CNE / CPE
Rush University Medical Center
Optimizing the Care of Mantle Cell Lymphoma: Translating the Latest Advances into Clinical Practice

Optimizing the Care of Mantle Cell Lymphoma: Translating the Latest Advances into Clinical Practice

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: July 26, 2021
Expires: July 25, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with mantle cell lymphoma.

Learning Objectives

After completing this program, participants should be able to:

  1. Summarize criteria required to accurately diagnose patients with mantle cell lymphoma and identify those most likely to benefit from treatment using prognostic indicators
  2. Evaluate the latest clinical data on the efficacy and safety of approved and investigational therapies for patients with mantle cell lymphoma
  3. Formulate best-practice treatment strategies for patients with mantle cell lymphoma, taking into consideration current guidelines and expert recommendations when individualizing treatment plans

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of mantle cell lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

The therapeutic field for MCL is rapidly expanding with an increasing number of targeted therapies, immunotherapies, and novel combination regimens. It is difficult for community oncologists, who see a limited number of patients with MCL, to keep pace with rapidly evolving treatment paradigms, as well as distinguish among these new and emerging strategies in order to best incorporate them into clinical practice.

As treatment for MCL evolves beyond conventional chemoimmunotherapies and ACST, clinicians will require familiarity with the unique safety considerations associated with targeted agents and immunotherapies in order to optimize clinical outcomes.

In addition, diagnosis of MCL presents a clinical challenge given that a community oncologist may only see a patient with MCL once or twice a year, and those patients may have radically different presentations and clinical behaviors. Clinicians are challenged to incorporate available diagnostic criteria, risk stratification, and prognostic indicators that can be used to personalize therapy decisions for this relatively rare hematologic malignancy.

Faculty

Jonathon B. Cohen, MD, MS
Associate Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Co-Director, Lymphoma Program
Winship Cancer Institute of Emory University
Medical Director, Infusion Services
Winship Cancer Institute of Emory University
Atlanta, Georgia

Conflict of Interest Policy/Disclosure Statement

Dr. Cohen has consulted for:
Loxo, Adaptive, Adicet, Cellectar, Beigene, AstraZeneca, Janssen, Pharmacyclics, Kite

Dr. Cohen has research grants from
Genentech, Novartis, BMS/Celgene, LOXO, LAM, BeiGene, Takeda, BioInvent, AstraZeneca

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Janssen Biotech, Inc. and Kite Pharma, Inc..

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: July 26, 2021
Expires: July 25, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with mantle cell lymphoma.

Learning Objectives

After completing this program, participants should be able to:

  1. Summarize criteria required to accurately diagnose patients with mantle cell lymphoma and identify those most likely to benefit from treatment using prognostic indicators
  2. Evaluate the latest clinical data on the efficacy and safety of approved and investigational therapies for patients with mantle cell lymphoma
  3. Formulate best-practice treatment strategies for patients with mantle cell lymphoma, taking into consideration current guidelines and expert recommendations when individualizing treatment plans

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of mantle cell lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

The therapeutic field for MCL is rapidly expanding with an increasing number of targeted therapies, immunotherapies, and novel combination regimens. It is difficult for community oncologists, who see a limited number of patients with MCL, to keep pace with rapidly evolving treatment paradigms, as well as distinguish among these new and emerging strategies in order to best incorporate them into clinical practice.

As treatment for MCL evolves beyond conventional chemoimmunotherapies and ACST, clinicians will require familiarity with the unique safety considerations associated with targeted agents and immunotherapies in order to optimize clinical outcomes.

In addition, diagnosis of MCL presents a clinical challenge given that a community oncologist may only see a patient with MCL once or twice a year, and those patients may have radically different presentations and clinical behaviors. Clinicians are challenged to incorporate available diagnostic criteria, risk stratification, and prognostic indicators that can be used to personalize therapy decisions for this relatively rare hematologic malignancy.

Faculty

Jonathon B. Cohen, MD, MS
Associate Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Co-Director, Lymphoma Program
Winship Cancer Institute of Emory University
Medical Director, Infusion Services
Winship Cancer Institute of Emory University
Atlanta, Georgia

Conflict of Interest Policy/Disclosure Statement

Dr. Cohen has consulted for:
Loxo, Adaptive, Adicet, Cellectar, Beigene, AstraZeneca, Janssen, Pharmacyclics, Kite

Dr. Cohen has research grants from
Genentech, Novartis, BMS/Celgene, LOXO, LAM, BeiGene, Takeda, BioInvent, AstraZeneca

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Janssen Biotech, Inc. and Kite Pharma, Inc..

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

1.00 CME / CNE / CPE
Rush University Medical Center
Improving Survival for Veterans with Bladder Cancer – Translating New Knowledge into Clinical Practice

Improving Survival for Veterans with Bladder Cancer – Translating New Knowledge into Clinical Practice

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: July 16, 2021
Expires: July 15, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with bladder cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Describe the current immune checkpoint inhibitors and guidelines for their use in patients with locally advanced or metastatic UC 
  2. Select appropriate strategies for the early detection and management of immune-related adverse events 
  3. Evaluate the latest clinical data on emerging and recently approved targeted approaches for the treatment of advanced and metastatic UC, including FGFR inhibitors, antibody-drug conjugates, and gene therapy 
  4. Formulate informed treatment plans for patients with locally advanced or metastatic UC within the VHA/MHS/DoD healthcare system based on patient-specific factors, latest best-practice treatment strategies, recent clinical trial data, and expert recommendations 

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of bladder cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

Best practices for UC are changing rapidly as new data continually emerges. Within the last 5 years, treatment of advanced and metastatic UC has expanded beyond chemotherapy to include ICIs, molecular targeted agents (ie, FGFR inhibitors), and ADCs. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the clinical utility of agents that could significantly impact patient outcomes. The rapidly expanding and evolving treatment landscape is challenging clinicians to stay abreast of latest advances. Lack of awareness regarding frequently updated guidelines, emerging clinical data, and optimal use of recently approved therapies may contribute to suboptimal care of patients with locally advanced and metastatic UC. Therefore, expert guidance in navigating the increasingly complicated treatment paradigm will benefit clinicians’ education, and ultimately improve outcomes for patients within the VHA/MHS/DoD healthcare system.

Faculty

Matthew D. Galsky, MD, FASCO
Professor of Medicine
Acting Chief, Division of Hematology and Medical Oncology
Icahn School of Medicine at Mount Sinai
Associate Director of Translational Research
Tisch Cancer Institute
New York, NY

Conflict of Interest Policy/Disclosure Statement

Dr. Galsky has consulted for:
BMS, AstraZeneca, Genentech, Novartis, Dendreon, Merck, RAPPTA Therapeutics, Dragonfly, Dracen, NuMab, Astellas, Seagen, EMD/Serono, Pfizer

Dr. Galsky has research grants from:
BMS, AstraZeneca, Genentech, Novartis, Dendreon, Merck

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Gilead, Janssen Biotech, Inc., and Merck.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: July 16, 2021
Expires: July 15, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with bladder cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Describe the current immune checkpoint inhibitors and guidelines for their use in patients with locally advanced or metastatic UC 
  2. Select appropriate strategies for the early detection and management of immune-related adverse events 
  3. Evaluate the latest clinical data on emerging and recently approved targeted approaches for the treatment of advanced and metastatic UC, including FGFR inhibitors, antibody-drug conjugates, and gene therapy 
  4. Formulate informed treatment plans for patients with locally advanced or metastatic UC within the VHA/MHS/DoD healthcare system based on patient-specific factors, latest best-practice treatment strategies, recent clinical trial data, and expert recommendations 

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of bladder cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

Best practices for UC are changing rapidly as new data continually emerges. Within the last 5 years, treatment of advanced and metastatic UC has expanded beyond chemotherapy to include ICIs, molecular targeted agents (ie, FGFR inhibitors), and ADCs. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the clinical utility of agents that could significantly impact patient outcomes. The rapidly expanding and evolving treatment landscape is challenging clinicians to stay abreast of latest advances. Lack of awareness regarding frequently updated guidelines, emerging clinical data, and optimal use of recently approved therapies may contribute to suboptimal care of patients with locally advanced and metastatic UC. Therefore, expert guidance in navigating the increasingly complicated treatment paradigm will benefit clinicians’ education, and ultimately improve outcomes for patients within the VHA/MHS/DoD healthcare system.

Faculty

Matthew D. Galsky, MD, FASCO
Professor of Medicine
Acting Chief, Division of Hematology and Medical Oncology
Icahn School of Medicine at Mount Sinai
Associate Director of Translational Research
Tisch Cancer Institute
New York, NY

Conflict of Interest Policy/Disclosure Statement

Dr. Galsky has consulted for:
BMS, AstraZeneca, Genentech, Novartis, Dendreon, Merck, RAPPTA Therapeutics, Dragonfly, Dracen, NuMab, Astellas, Seagen, EMD/Serono, Pfizer

Dr. Galsky has research grants from:
BMS, AstraZeneca, Genentech, Novartis, Dendreon, Merck

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Gilead, Janssen Biotech, Inc., and Merck.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Pages